{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enbrel&page=3", "query": { "intervention": "Enbrel", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 167, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enbrel&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enbrel&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T16:27:24.347Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00005007", "title": "Etanercept for Wegener's Granulomatosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Wegener's Granulomatosis" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": null, "sex": "ALL", "summary": "11 Years and older" }, "enrollment_count": 181, "start_date": "2000-06", "completion_date": "2003-03", "has_results": false, "last_update_posted_date": "2007-12-28", "last_synced_at": "2026-10-19T16:27:24.347Z", "location_count": 8, "location_summary": "San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005007" }, { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-12-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-19T16:27:24.347Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" }, { "nct_id": "NCT04559412", "title": "Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Sofusa DoseConnect", "type": "DEVICE" }, { "name": "Enbrel", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Sorrento Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 11, "start_date": "2021-03-15", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2023-04-12", "last_synced_at": "2026-10-19T16:27:24.347Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04559412" }, { "nct_id": "NCT02346240", "title": "Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Plaque Psoriasis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Etanercept", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 559, "start_date": "2015-02-11", "completion_date": "2018-12-17", "has_results": true, "last_update_posted_date": "2021-07-16", "last_synced_at": "2026-10-19T16:27:24.347Z", "location_count": 19, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02346240" }, { "nct_id": "NCT03294954", "title": "GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "GINAKIT Cells", "type": "GENETIC" }, { "name": "GINAKIT cells + Etanercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "GENETIC", "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 70, "start_date": "2018-01-18", "completion_date": "2040-08-10", "has_results": false, "last_update_posted_date": "2025-09-19", "last_synced_at": "2026-10-19T16:27:24.347Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03294954" }, { "nct_id": "NCT04798287", "title": "Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tofacitinib", "type": "DRUG" }, { "name": "TNF Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105711, "start_date": "2021-03-10", "completion_date": "2022-05-16", "has_results": false, "last_update_posted_date": "2022-06-22", "last_synced_at": "2026-10-19T16:27:24.347Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04798287" }, { "nct_id": "NCT02112097", "title": "ASIS for Enbrel in Plaque Psoriasis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Plaque Psoriasis." ], "interventions": [ { "name": "Gadolinium", "type": "DRUG" }, { "name": "Efficacy of Enbrel subcutaneously at Week 12", "type": "DRUG" }, { "name": "Efficacy of Enbrel subcutaneously at Week 24", "type": "DRUG" }, { "name": "Efficacy of Enbrel subcutaneously at Week 36", "type": "DRUG" }, { "name": "Efficacy of Enbrel subdermally at Week 12", "type": "DRUG" }, { "name": "Efficacy of Enbrel subdermally at Week 24", "type": "DRUG" }, { "name": "Efficacy of Enbrel subdermally at Week 36", "type": "DRUG" }, { "name": "PASI 75 n(%) subcutaneously at Week 12", "type": "DRUG" }, { "name": "PASI 75 n(%) subcutaneously at Week 24", "type": "DRUG" }, { "name": "PASI 75 n(%) subcutaneously at Week 36", "type": "DRUG" }, { "name": "PASI 75 n(%) subdermally at Week 12", "type": "DRUG" }, { "name": "PASI 75 n(%) subdermally at Week 24", "type": "DRUG" }, { "name": "PASI 75 n(%) subdermally at Week 36", "type": "DRUG" }, { "name": "Adverse Reactions of Enbrel subcutaneously", "type": "DRUG" }, { "name": "Adverse Reactions of Enbrel subdermally at Week 36", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ASIS Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2016-01", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-10-19T16:27:24.347Z", "location_count": 1, "location_summary": "Westminster, California", "locations": [ { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02112097" }, { "nct_id": "NCT02694770", "title": "A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation" ], "interventions": [ { "name": "Neihulizumab Treatment", "type": "BIOLOGICAL" }, { "name": "Conventional Treatment", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbGenomics B.V Taiwan Branch", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-07", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2016-04-25", "last_synced_at": "2026-10-19T16:27:24.347Z", "location_count": 2, "location_summary": "Houston, Texas • Seattle, Washington", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02694770" }, { "nct_id": "NCT00141713", "title": "The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft-Versus-Host Disease" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2003-10", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2013-03-13", "last_synced_at": "2026-10-19T16:27:24.347Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00141713" }, { "nct_id": "NCT02987257", "title": "NATIENS: Optimal Management and Mechanisms of SJS/TEN", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stevens-Johnson Syndrome", "Toxic Epidermal Necrolyses" ], "interventions": [ { "name": "Harmonized supportive care", "type": "DRUG" }, { "name": "Etanercept 50 mg sc day 1 and day 4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-03-21", "completion_date": "2025-10-31", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-10-19T16:27:24.347Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02987257" } ] }